Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 E180R |
Therapy | Cytarabine + Doxorubicin |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 E180R | acute myeloid leukemia | sensitive | Cytarabine + Doxorubicin | Preclinical | Actionable | In a preclinical study, the combination of Cytosar-U (cytarabine) and Adriamycin (doxorubicin) inhibited tumor growth and increased survival (p<0.0001) compared to control treatment in a mouse model of acute myeloid leukemia harboring TP53 E177R (corresponding to E180R in human) (PMID: 34907344). | 34907344 |
PubMed Id | Reference Title | Details |
---|---|---|
(34907344) | p53 partial loss-of-function mutations sensitize to chemotherapy. | Full reference... |